APA (7th ed.) Citation

Liu, D., Gong, J., Li, J., Qi, C., Niu, Z., Liu, B., . . . Shen, L. (2025). Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer. Signal Transduction and Targeted Therapy, 10(1), 1. https://doi.org/10.1038/s41392-025-02195-x

Chicago Style (17th ed.) Citation

Liu, Dan, et al. "Efficacy and Safety of KN026, a Bispecific Anti-HER2 Antibody, in Combination with KN046, an Anti-CTLA4/PD-L1 Antibody, in Patients with Advanced HER2-positive Nonbreast Cancer." Signal Transduction and Targeted Therapy 10, no. 1 (2025): 1. https://doi.org/10.1038/s41392-025-02195-x.

MLA (9th ed.) Citation

Liu, Dan, et al. "Efficacy and Safety of KN026, a Bispecific Anti-HER2 Antibody, in Combination with KN046, an Anti-CTLA4/PD-L1 Antibody, in Patients with Advanced HER2-positive Nonbreast Cancer." Signal Transduction and Targeted Therapy, vol. 10, no. 1, 2025, p. 1, https://doi.org/10.1038/s41392-025-02195-x.